Physician profile
Kimberly M Eads
NPI 1033502794
$301,956.83
in general payments reported to CMS, 2019-2025
18 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $40K · 2023: $50K · 2024: $94K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Travel and Lodging: $67K · Food and Beverage: $7,147 · Consulting Fee: $3,188 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173,028.00 |
| Travel and Lodging | $66,876.32 |
| Food and Beverage | $7,146.76 |
| Consulting Fee | $3,187.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $247,322.09 | 2021-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $44,504.33 | 2021-2024 | Tremfya |
| Eli Lilly and Company | $9,067.50 | 2022-2024 | |
| Almirall LLC | $300.00 | 2021 | |
| Abbvie INC. | $195.99 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $94.53 | 2021-2025 | |
| Ucb, INC. | $65.02 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $62.68 | 2025 | |
| Leo Pharma INC. | $53.22 | 2022-2025 | Anzupgo |
| Regeneron Healthcare Solutions, INC. | $48.39 | 2025 | Dupixent |
| Biofrontera INC. | $43.45 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Lilly USA, LLC | $41.54 | 2021-2025 | Ebglyss |
| Incyte Corporation | $37.24 | 2025 | Opzelura |
| Pfizer INC. | $30.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.67 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.99 | 2025 | |
| Genzyme Corporation | $19.87 | 2025 | |
| Galderma Laboratories, L.P. | $18.81 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Eads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.